Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer by Dubeykovskaya, Zina et al.
ARTICLE
Received 16 Sep 2015 | Accepted 16 Dec 2015 | Published 4 Feb 2016
Neural innervation stimulates splenic TFF2 to
arrest myeloid cell expansion and cancer
Zina Dubeykovskaya1,*, Yiling Si1,*, Xiaowei Chen1, Daniel L. Worthley1, Bernhard W. Renz1,2,
Aleksandra M. Urbanska1, Yoku Hayakawa1, Ting Xu1, C. Benedikt Westphalen1, Alexander Dubeykovskiy1,
Duan Chen3, Richard A. Friedman4, Samuel Asfaha1, Karan Nagar1, Yagnesh Tailor1, Sureshkumar Muthupalani5,
James G. Fox5, Jan Kitajewski6 & Timothy C. Wang1
CD11bþGr-1þ myeloid-derived suppressor cells (MDSCs) expand in the spleen during
cancer and promote progression through suppression of cytotoxic T cells. An anti-
inﬂammatory reﬂex arc involving the vagus nerve and memory T cells is necessary for
resolution of acute inﬂammation. Failure of this neural circuit could promote procarcinogenic
inﬂammation and altered tumour immunity. Here we show that splenic TFF2, a secreted
anti-inﬂammatory peptide, is released by vagally modulated memory T cells to suppress the
expansion of MDSCs through CXCR4. Splenic denervation interrupts the anti-inﬂammatory
neural arc, resulting in the expansion of MDSCs and colorectal cancer. Deletion of Tff2
recapitulates splenic denervation to promote carcinogenesis. Colorectal carcinogenesis could
be suppressed through transgenic overexpression of TFF2, adenoviral transfer of TFF2 or
transplantation of TFF2-expressing bone marrow. TFF2 is important to the anti-inﬂammatory
reﬂex arc and plays an essential role in arresting MDSC proliferation. TFF2 offers a potential
approach to prevent and to treat cancer.
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olorectal cancer is a leading cause of cancer death1.
Chronic inﬂammatory conditions, such as ulcerative
colitis and Crohn’s disease, increase the risk of colorectal
cancer2. Inﬂammation and cancer are associated with increased
myeloid CD11bþGr-1þ cells, and these MDSCs suppress host
immunity3,4.
The autonomous nervous system regulates acute inﬂammation
through a cholinergic anti-inﬂammatory reﬂex5,6. On vagal
activation, acetylcholine released from memory CD4þChATþ
T cells binds to nicotinic receptors on macrophages, thus
inhibiting cytokine production. However, the importance of
the nervous system in the modulation of tumorigenesis through
the anti-inﬂammatory reﬂex has not been studied.
Secreted protein trefoil factor 2 (TFF2) is produced in the
stomach and duodenum where it possibly maintains mucosal
integrity and restitution7–9. TFF2 mRNA has been detected also in
primary and secondary lymphatic organs in rodents, but the precise
cellular source and role of TFF2 in the immune compartment is not
known10,11. While recombinant TFF2 attenuates colitis, the
mechanisms involved have not been fully deﬁned12.
In this report we show that TFF2 is expressed predominantly in
splenic memory T cells, where it is regulated by the vagus nerve
and suppresses colon carcinogenesis. Suppression of cancer by
TFF2 was abrogated following surgical disruption of vagal
innervation. Thus, we have extended the vagal efferent arc from
suppression of acute inﬂammation to a role in coordinating
procarcinogenic inﬂammation.
Results
Splenic TFF2 is regulated by vagal nerve. TFF2 protein is
expressed in the spleen under normal physiological conditions
(Fig. 1a). Following chemically induced colitis model (2.5%
dextran sodium sulfate (DSS) ad libitum for 5 days), we observed
a marked increase in splenic Tff2 expression within 24–72 h that
subsided over 19 days (14 days after stopping DSS, Fig. 1b,c). As
TFF2 expression returned to baseline (at 19 days), splenic
immature myeloid cells (IMCs) appeared to reach their peak
(Supplementary Fig. 1a). Splenic Tff2 expression is upregulated by
the T-cell mitogen concanavalin A (Supplementary Fig. 1b), and
we established that it was the splenic T cells, speciﬁcally,
CD44hiCD62Llo memory T cells that expressed the highest levels
of TFF2 (Fig. 1d and Supplementary Fig. 1c,d), as conﬁrmed by
quantitative reverse transcriptase–PCR (qRT–PCR; Fig. 1e),
immunohistochemistry (Fig. 1f) and also by Tff2 quantitative
PCR in sorted choline acetyltransferase-enhanced green ﬂuor-
escent protein (ChAT-EGFP) cells (Fig. 1g). ChAT-EGFP labels
an important subset of memory T cells expressing acetylcholine6.
In addition, DSS treatment increases TFF2–EGFP-expressing
memory T cells (Supplementary Fig. 1e).
Memory T cells have been implicated in the vagal efferent
immunosuppressive circuit, also known as the cholinergic
anti-inﬂammatory pathway6,13. We hypothesized that TFF2
expression in memory T cells was also regulated by the vagus
nerve. Indeed, vagal nerve stimulation, mimicking the
inﬂammatory neural circuit, resulted in the increase of splenic
Tff2 expression (Fig. 1h). Conversely, in mice with
subdiaphragmatic bilateral truncal vagotomy with pyroplasty
(VTPP) mice, the splenic Tff2 response to DSS was lost
(compared with control mice treated by pyloroplasty alone,
Supplementary Fig. 1f). Importantly, this circuit could be partially
recapitulated in vitro by the addition of isoproterenol (mimicking
post-ganglionic vagal stimulation) to sorted splenic CD4 cells,
resulting in upregulation of Tff2 mRNA in a dose-dependent
manner (Fig. 1i). Thus, the vagal pathway is important for Tff2
expression in splenic T cells.
TFF2 reduces colonic tumorogenesis. Tff2-null mice that lack
both epithelial and splenic TFF2 do not differ from wild-type at a
basal level14; however, they develop more severe colitis following
DSS treatment11. To determine the relevance of T cell-speciﬁc
TFF2 production in this acute phase response, we generated
CD2–Tff2 transgenic mice that express mouse TFF2 under a
T cell-speciﬁc human CD2 promoter (Supplementary Fig. 2a–d).
CD2–Tff2 mice do not have any phenotype at baseline, with
normal blood counts, body weight and life span (Supplementary
Fig. 2e,f and Tables 1, 2).
However, on DSS treatment CD2–Tff2 mice showed
insigniﬁcant expansion of CD11bþGr-1þ IMCs, while Tff2-null
mice had an exaggerated splenic IMC response with
splenomegaly compare with wild-type and CD2–Tff2 mice
(Fig. 2a,b and Supplementary Fig. 1a). Importantly, there were
only minor differences in colonic inﬂammation between Tff2-null
and wild-type controls and thus we interpreted the massive
increase in IMCs in the Tff2-null mice to reﬂect an extracolonic
process (Supplementary Fig. 3a–d). During chronic continuous
dosing with DSS, Tff2-null mice died earlier than both wild-type
and CD2–TFF2 animals, but there were no differences in body
weight loss during acute colitis, and little difference in cytokine
levels, except for a higher colonic interleukin-1b (IL-1b) and IL-6
level in Tff2-null mice, with lower levels in CD2–Tff2 mice
(Supplementary Fig. 3a–d).
It has been proposed that TFF2 contributes to the
cytoprotective barrier in the gut8. However, TFF2 was not
detected at the protein level in the colonic mucosa
(Supplementary Fig. 3e) and there was no difference in colonic
permeability between Tff2-null, CD2–Tff2 and wild-type mice in
the DSS model (Supplementary Fig. 3f). Thus, TFF2 did not
signiﬁcantly contribute to the colonic mucosal barrier and the
increased expansion of immature myeloid cells and slightly
worsened colitis after DSS in TFF2-null mice was not due to
direct colonic effects by TFF2.
The inverse relationship between TFF2 status and IMC
response to injury was more striking in the azoxymethane
(AOM)/DSS model of inﬂammatory colorectal carcinogenesis,
again with a pronounced biological gradient across the
TFF2 groups. Five months after AOM/DSS treatment
the proportion of splenic MDSCs was lowest in the CD2–Tff2
mice that also developed signiﬁcantly fewer tumours (Fig. 2c–e
and Supplementary Fig. 4a). In contrast, the Tff2-null mice had
the most MDSCs and exhibited the greatest number of tumours,
which showed a higher dysplasia grade and a greater area
of dysplasia by both histology and nuclear b-catenin
immunostaining (Fig. 2c–g and Supplementary Fig. 4a,b). Tff2
mRNA was undetectable in colon of wild-type and CD2–Tff2
mice treated with AOM/DSS; however, in contrast to decreased
Tff2 mRNA in the spleen of wild-type mice, the level of Tff2
mRNA in the spleens of CD2–Tff2 mice remained quite high
(Supplementary Fig. 4c). Thus, given the absence of signiﬁcant
colonic TFF2 expression expansion of MDSC and tumour burden
were inversely associated with splenic TFF2 status.
Loss of TFF2 promotes the expansion of MDSCs. In the AOM/
DSS model, CD11bþGr-1þ cells in the spleen and colonic
tumours were heterogeneous, but with a preponderance of Ly-
6Gþ over Ly-6Cþ subset (Supplementary Fig, 4d–f). Splenic
CD11bþGr-1þ cells from wild-type and TFF2-null mice showed
low expression of CD40 antigen, moderate level of CD86, variable
expression of CD11c, CD31, CD115 and major histocompatibility
complexII, and high expression of F4/80, CD80 and PD-L1
(Supplementary Fig. 5a). Both CD80 and PD-L1 suppress anti-
tumoral T-cell cytotoxicity in cancer15,16 and also could be
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detected on MDSC in tumour (Supplementary Fig. 5b). Splenic
CD11bþGr-1þCD80þ cells inhibited INF-g production
(Supplementary Fig. 5c) and the in vitro proliferation of CD4þ
T cells activated with CD3/CD28 antibody (Fig. 3a). Neutralizing
CD80 antibody abrogated the MDSC suppression of T-cell
proliferation (Supplementary Fig. 5d). In contrast, splenic
CD11bþGr-1þ cells from CD2–Tff2 mice expressed low levels
of CD80 and did not suppress proliferation or interferon-g (IFN-g)
expression of activated T cells (Supplementary Fig. 5a,e,f). Splenic
CD11bþGr-1þ cells from Tff2-null and wild-type mice express
higher arginase I activity compared with those from CD2–Tff2
mice, and lower nitric oxide (NO) activity, but generate high levels
of ROS (reactive oxygen species; Supplementary Fig. 5g–i).
Together, these data conﬁrm that TFF2 from T cells suppresses
the development of splenic MDSCs, which may be a critical step in
modulating cancer risk.
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Figure 1 | TFF2 is expressed in CD4þ memory Tcells and regulated by the vagus nerve. (a) Identiﬁcation of TFF2 peptide in normal spleen of wild-type
mice by western blot. (b,c) Time-course change of the TFF2 protein (b) and mRNA (c) in spleen of wild-type mice after 2.5% DSS treatment. Data
shown are representative of two experiments for each analysis. Data is mean±s.e.m of triplicate determinations, **Po0.01, unpaired t-test, two-tailed.
(d) Detection of Tff2 mRNA in T cells in untreated wild-type mice by semi-quantitative RT-PCR. Total mRNA from splenic T and B cells was isolated from
wild-type mice and then Tff2 mRNA was analysed along with T cells marker Thy 1.2 (second panel), B cells marker CD19 (third panel) or b-actin (quality
control, bottom panel). (e) Expression of Tff2 is upregulated most in splenic memory CD4þ T cells after DSS treatment. Unpaired t-test, two-tailed, the
value present mean±s.e.m., **Po0.0001. (f) Localization of TFF2 protein in splenic CD44þ Tmemory cells (scale 10mm). (g) expression of Tff2 mRNA in
ChATþ Tmemory cells. Unpaired two-tailed t-test, data is mean±s.e.m., *Po0.05. (h) Splenic Tff2 RNA is upregulated by vagus nerve stimulation (VNS)
but not in Sham mice. Unpaired two-tailed t-test, data is mean±s.e.m., *Po0.05. (i) Isoproterenol upregulated Tff2 mRNA expression in CD4þ T cells
in vitro. Unpaired two-tailed t-test, data is mean±s.e.m., *Po0.05 and **Po0.01.
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There was a signiﬁcant accumulation of CXCR4-expressing
MDSCs around colonic tumours (50- to 100-fold), along with
increased expression of pro-tumorigenic cytokines IL-17A and
IL-1b (Fig. 3b and Supplementary Fig. 6a–d), in Tff2-null and
wild-type mice compared with CD2–Tff2 mice. IL-17A is a key
cytokine promoting colonic tumorigenesis, stimulating and
mobilizing granulocytes into sites of inﬂammation17,18. As
expected, MDSCs from tumours generate high ROS activity
(Supplementary Fig. 5i). Interestingly, the number of dendritic cells
(deﬁned as CD45þLy-6G-F4/80CD11bþCD11cþ ) was higher
in tumours from CD2–Tff2 mice versus tumours from the other
two groups, suggesting a protective role for dendritic cells
(Supplementary Fig. 6e). To prove that CD11bþGr-1þ cells
directly contributed to tumour progression, we performed adoptive
transfer of MDSC sorted from spleen and bone marrow of tumour-
bearing Tff2-null mice into AOM/DSS-treated CD2–Tff2 mice19.
The transfer of MDSCs from Tff2-null mice resulted in a marked
(10-fold) stimulation of tumour growth in CD2–Tff2 mice
(Fig. 3c,d), converting the tumour-resistant CD2–Tff2 mice into a
tumour susceptible phenotype.
CD8 T cells play a key protective role in anti-tumour immune
response in colorectal neoplasia20,21. Depletion of CD8þ T cells
in CD2–Tff2 mice treated with AOM/DSS resulted in a marked
(10-fold) increase of tumour growth (Fig. 3e,f), indicating that the
protective effect of Tff2 overexpression depended on CD8þ
T-cell immunity. Splenic CD8þ T cells from AOM/DSS-treated
CD2–Tff2 express higher levels of IFN-g and granzyme
B (GrB) compared with splenic CD8þ T cells from AOM/DSS
Tff2-null mice (Fig. 3g). There was a direct relationship in the
AOM/DSS model between colonic CD8þ T cells and TFF2
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Figure 2 | TFF2 status was associated with the expansion of IMC/MDSCs and development of colorectal cancer. (a,b) DSS treatment results in
splenomegaly (a) and accumulation of CD11bþGr-1þ cells (b) in Tff2-null and wild-type mice, but not in CD2–Tff2 counterparts. Representative data from
two independent experiments, 3–6 mice per group for each time point. NS, non-signiﬁcant, *Po0.05, ***Po0.001, ****Po0.0001, analysis of variance
(ANOVA) test following Sidak’s multiple comparison test. (c) Highest accumulation of splenic CD11bþGr-1þ cells in TFF2-null mice compare with wild-
type and CD2–Tff2 mice 5 months after AOM/DSS treatment. Data shown are representative of at least ﬁve experiments, n¼ 3–6 mice in each group,
Sidak’s multiple comparison test after ANOVA test (d) Representative colons of Tff2-null, wild-type and CD2–Tff2 mice 5 months after AOM/DSS
treatment. (e) Tumour number was inversely related to Tff2 status. Data shown are representative of at least four experiments, n¼ 3–6 mice in each group,
*Po0.05, ****Po0.0001, Sidak’s multiple comparison test after ANOVA test (f) Representative hematoxylin and eosin staining of colon from CD2–Tff2,
wild-type and Tff2-null mice. Scale bars are 800 mm (left panels) and 160mm (right panels). (g) Tff2-null mice show higher dysphasia score (**P¼0.008,
Kruskal–Wallis test) and dysplasia area (**Po0.01, Holm–Sidak’s multiple comparison test after ANOVA test), n¼ 5–10 mice in group, evaluation of
AOM-DSS-treated (5 months) CD2–Tff2, wild-type and Tff2-null mice.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10517
4 NATURE COMMUNICATIONS | 7:10517 | DOI: 10.1038/ncomms10517 | www.nature.com/naturecommunications
status, with Tff2-null mice having no detectable colonic CD8
mRNA expression (Supplementary Fig. 6f). AOM/DSS-treated
wild-type mice receiving splenic IMCs from untreated CD2–Tff2
mice developed a lower number of tumours and a lower
proportion of MDSC but a higher proportion of CD8þ cells in
the colon compared with wild-type mice that received splenic
IMC from Tff2-null mice (Fig. 3h–k). These data indicate a
critical role for the spleen in the development of early MDSCs.
Overall, the association between splenic Tff2 and cancer risk is in
keeping with the well-recognized pro-tumorigenic effect of
MDSCs and their suppression of tumoricidal CD8þ T cells20,22.
The importance of T cells as a source of TFF2, as opposed to
epithelial gastric cells, was conﬁrmed by bone marrow
transplantation of CD2–Tff2, wild-type or Tff2-null donor
bone marrow into wild-type mice (5–6 mice per group), followed
by the DSS colitis protocol. Wild-type mice that received
CD2–Tff2 bone marrow suffered the mildest colitis, while
recipients of Tff2-null bone marrow had slightly more severe
disease (measured by weight loss, spleen size, colonic shortening
and colonic IL-1b expression) (Supplementary Fig. 7a–d).
More importantly, following the AOM–DSS protocol, recipients
of Tff2-null bone marrow as expected developed the
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greatest tumour burden (n¼ 3 per group, Supplementary
Fig. 7e).
TFF2 deﬁciency is responsible for the expansion of MDSCs.
DSS treatment resulted in proliferation of CD11bþGr-1þ cells in
the spleen that was inhibited in a TFF2-dependent fashion
(Fig. 4a,b and Supplementary Fig. 8a). A pulse of BrdU 3 h before
sacriﬁce revealed that the Tff2-null mice had the greatest
proportion of proliferating IMCs (13%) followed by wild-type
(8%) and CD2–Tff2 (1%) mice (Supplementary Fig. 8a).
Recombinant TFF2 (rTFF2) directly inhibited IMC proliferation
in vitro in a dose-dependent gradient (Fig. 4c), mediated, at least
in part, by downregulation of cyclin D1 mRNA in IMCs/MDSCs
(Supplementary Fig. 8b,c). TFF2 deﬁciency enhanced the
colony forming unit potential of splenocytes grown in
granulocyte-macrophage progenitor propagating media (Fig. 4d)
and the proportion of splenic granulocyte-macrophage
progenitors (Lin IL-7Ra c-kitþSca-1-CD16/32hiCD34þ ) by
ﬂow cytometry (Supplementary Fig. 8d). Thus, TFF2 released
from splenic T cells suppressed proliferation of early splenic
myeloid progenitors.
TFF2 suppresses myeloid cells via CXCR4 receptor. To identify
likely candidates for TFF2-mediated suppression of myeloid cell
expansion, we performed gene expression microarray.
DSS-induced splenic CD11bþGr-1þ cells from Tff2-null mice
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were cultured with granulocyte–macrophage colony-stimulating
factor (GM-CSF) only (control) or GM-CSF plus puriﬁed mouse
rTFF2 (Supplementary Fig. 8e). We compared the gene
expression proﬁles of TFF2-treated and -untreated IMCs. 5,810
genes had a greater than twofold change in expression
(Supplementary Table 3). Positive regulators of cell cycle (cyclin
D1 and cyclin E1) were downregulated (eight- and twofold,
accordingly), while negative regulators of cell cycle (such as
Nurp1) were upregulated, in keeping with TFF2-mediated
suppression of IMC proliferation (validated by qRT–PCR,
Supplementary Fig. 8f and Supplementary Table 3). ApoE was
one of the most upregulated genes (B90-fold), a ﬁnding con-
ﬁrmed by qRT–PCR (Supplementary Fig. 8g and Supplementary
Table 3). ApoE has been shown to retard metastasis23,24, and cell-
surface proteoglycan-bound ApoE can directly suppress the
proliferation of haematopoietic stem and progenitor cells,
limiting expansion of myeloid cells23. Indeed, addition of rTFF2
to sorted IMCs induced the expression of the biologically relevant
cell-bound ApoE (Fig. 4e). The suppression of tumour growth in
response to TFF2 overexpression in the AOM/DSS model was
not, however, signiﬁcantly altered by knockout of the ApoE gene
(Supplementary Fig. 8h), suggesting that there may be other
important signalling targets beyond ApoE.
The CXCR4 receptor is highly expressed on MDSC from blood
and colonic tumour tissues from CRC patients25 and TFF2 binds
to and acts through the CXCR4 receptor26–29, CXCR4 expression
on splenic CD11bþGr-1þ cells was increased in DSS-treated and
in tumour-bearing mice (Supplementary Fig. 8i,j). Given the close
association between rTFF2 treatment of IMCs and suppression of
cyclin D1, we measured the expression of cyclin D1 to test
whether TFF2 suppressed proliferation of MDSC through the
CXCR4 receptor. We used AMD3100 to block CXCR4 on IMCs
in vitro (Fig. 4f). Treatment with AMD3100 reduced the
TFF2-mediated downregulation of cyclin D1 (up to 80%), while
AMD3100 alone had no effect on cyclin D1 level.
If TFF2 expression by splenic CD4 T cells is a component of
the anti-inﬂammatory reﬂex, it should follow that physical
disruption of splenic innervation would accelerate tumorigenesis
in the AOM/DSS model. To speciﬁcally denervate the spleen
without otherwise altering innervation of the gastrointestinal
tract, we resected nerves along the splenic artery. Wild-type mice
with splenic denervation (SpDnx) showed a statistically greater
tumour number along with higher proportion of MDSC in spleen
and bone marrow compared with control (Sham) mice receiving
Sham surgery (Fig. 4g,h and Supplementary Fig. 8k–m). Thus,
SpDnx in the setting of carcinogenesis leads to a marked increase
in myeloid cell expansion and more rapid progression to
colorectal cancer.
TFF2 gene delivery confers therapeutic effect on cancer. Having
established splenic TFF2 as an important factor within the vagally
mediated anti-inﬂammatory reﬂex arc, we wondered whether
exogenous TFF2 delivery could be used to suppress MDSCs and
cancer. We infected Tff2-null and wild-type mice with an
adenovirus vector Ad-Tff2 that expressed mouse TFF2 or a
control vector Ad-Fc expressing the Fc fragment of IgG
(Supplementary Fig. 9a,b). After one dose of Ad-Tff2 (5 108
pfu/mouse), TFF2 was detected in peripheral blood of Tff2-null,
wild-type and nonobese diabetic/severe combined immunodeﬁ-
ciency (NOD–SCID) mice (Fig. 5a). Both wild-type and Tff2-null
mice injected with Ad-Tff2 had fewer peripheral MDSCs in blood
and spleen (Fig. 5b,c and Supplementary Fig. 9c), and developed
signiﬁcantly fewer tumours versus control (Fig. 5d-g). On histo-
pathology, the area of dysplasia was signiﬁcantly reduced in
Ad-Tff2 treated versus control mice (Fig. 5h,i). In contrast, there
was no difference in tumour number in immunodeﬁcient
Rag2 / mice injected with Ad-TFF2 versus Ad-Fc adenovirus
(Supplementary Fig. 9d), indicating once again that TFF2
suppresses tumorigenesis via the adaptive immune system.
Discussion
Splenic TFF2 is a secreted peptide expressed predominantly in
memory T cells, co-localized with ChAT-EGFP cells shown to
mark memory CD4þ T cells6. TFF2 is induced in vivo by vagal
stimulation and in vitro in CD4þ T cell by adrenergic
stimulation, and induction by DSS treatment was blocked by
vagotomy. Thus, splenic TFF2 is regulated by the inﬂammatory
reﬂex, which in the acute setting results in the release of
acetylcholine by memory CD4þ T cells and suppression of tumor
necrosis factor-a production by macrophages6. Our ﬁndings
suggest that the production of TFF2 by ChATþ T cells
represents a more delayed response, preventing proliferation of
myeloid progenitors and the development of MDSCs following
chronic stress. In contrast to the mild reduction in histologic
colitis in CD2–Tff2 transgenic mice in response to DSS treatment,
we noted marked reduction in later tumour development in
response to AOM/DSS. This was due to a reduction in MDSCs,
since tumour suppression could be overcome by adoptive transfer
of MDSCs from TFF2-null mice, and abrogated by immune
depletion of CD8þ T cells.
MDSCs are increased in blood and tumour tissues from
patients with advanced colorectal cancer30–32. In the setting of
cancer and inﬂammation, the spleen becomes an important
source of myeloid cells in animal models and human patients33,34.
MDSCs suppress T-cell immunity through PD-L1, Arg-1, iNOS
and ROS, although they also have direct pro-tumorigenic
effects25. TFF2 acts via CXCR4 receptor that is highly expressed
on MDSCs in patients with ovarian cancer, promoting their
accumulation35, and on MDSCs in colorectal cancer25. Previous
studies have shown that TFF2 binds to CXCR4 with low afﬁnity26
and while relatively high concentrations (0.5–0.8 mM) of trefoil
peptides are required for signalling36–38, the normal physiologic
concentration of TFF2 may be high39. Further studies are
needed to explore possible correlations between circulating
TFF2 and the levels of MDSC. TFF2 upregulated ApoE but
ApoE / /CD2–Tff2 mice did not develop signiﬁcantly more
tumours than CD2–Tff2 mice, suggesting some functional
redundancy within this system. Overexpression of TFF2 led to
a slight increase in tumour-associated dendritic cells, which might
also contribute to tumour immunity. Finally, SpDnx in wild-type
mice treated with AOM/DSS also resulted in both a marked
increase in MDSCs and in tumour development, conﬁrming the
importance of the anti-inﬂammatory reﬂex in modulating
tumour immunity.
TFF2 is lowly expressed in the intestine10, but no TFF2 protein
could be detected in the colon of our AOM/DSS-treated mice.
Furthermore, the relative sufﬁciency of TFF2 did not impact on
intestinal barrier function. Thus, it is unlikely that local colonic
production of TFF2 was responsible for the observed effects. The
contribution of circulating TFF2, derived from the stomach, could
not be absolutely excluded40. However, we observed marked
differences in tumour development in mice that received wild-
type versus TFF2-null versus CD2–Tff2 bone marrow transplants,
thus indicating the predominant role of hematopoietic, rather
than epithelial, TFF2 expression at least for colorectal
carcinogenesis. Finally, the marked increase in colonic tumour
development following SpDnx underscores the critical role for the
splenic response to carcinogenic stress. Our model, informed by
earlier work, begins with the release of noradrenaline from the
post-ganglionic vagus nerve in response to injury (Supplementary
Fig. 10). This stimulates splenic memory T cells to upregulate
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TFF2 expression that acts in a paracrine fashion on local
IMC/MDSCs and myeloid progenitors via the CXCR4 receptor.
TFF2 suppresses IMC/MDSC proliferation in part through
downregulation of cyclin D1 (and possibly through
upregulation of cell-bound ApoE) thus reducing MDSCs and
liberating anti-tumorigenic CD8þ T cells to inhibit the
development of cancer. This vagally mediated circuit can be
enhanced by exogenous delivery of TFF2, either through bone
marrow transplantation or by an adenoviral vector, both of which
suppressed MDSCs and prevented cancers. These data indicate
that TFF2 is a critical component in suppressing splenic MDSCs
as a part of the vagal inﬂammatory reﬂex, and suggests its
potential utility in combined cancer therapy.
Methods
Mice. C57/BL6 wild-type, Rag2 / , B6.129P2-Apoetm1Unc/J mice were purchased
from Jackson Laboratories (Bar Harbor, ME), Tff2-null mice were described
earlier14, TFF2–BAC–EGFP–Cre transgenic mice that express an EGFP–Cre fusion
protein and CD2–Tff2 mice were generated in our laboratory, both on C57BL/6
background, Cxcr4::EGFP mice (also on C57BL/6 background) were kindly
provided by Richard J. Miller (Northwestern University Medical School, USA). Sex
and age matched mice were used at 6–12 weeks of age. To generate the CD2–Tff2
mice, the mouse gene Tff2 was cloned downstream into hCD2 promoter into EcoRI
site of expressing vector. For this purpose site for EcoRI site was incorporated in
primers for PCR ampliﬁcation of mouse Tff2 sequence using respective mouse
complementary DNA (cDNA) library clone BC050086 (Open Biosystem,
Baltimore, MD). The forward primer was 50-ATTGAATTCGCCACCATGCGACC
TCGAGATGCC-30 . The reverse primer was 50-AATTGAATTCTCAGTAGTG
ACAATCTTCCACAGAC-30. Resulting construct was transfected into Escherichia
coli Stbl2 competent cells, clones were veriﬁed for presence and proper orientation
of Tff2 gene by sequencing using forward primer located in CD2 and reverse
primer located within TFF2 sequence. Transgenic mouse lines expressing the Tff2
protein in T cells were generated in Transgenic Core Facility of Columbia
University, on a B6CBA/F2 background. The offspring were screened for transgene
integration by PCR analysis using primers selected for promoter part of CD2 and
Tff2 gene. The offspring were tested for the presence of transgenic CD2–Tff2
mRNA transcript spleen and thymus. Transgenic mice were backcrossed to
C57BL/6 for more than 10 generations before using in experiments. All animal
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Figure 5 | Adenoviral delivery of TFF2 reduced colorectal carcinogenesis. (a) Detection of recombinant TFF2 by western blot in serum from Tff2-null,
NOD-SCID and WTmice 5 days after Ad-mTff2 treatment (5 108 pfu per mouse). (b,c) Ad-Tff2 reduced splenic CD11bþGr-1þ cells compared to the
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wild-type mice (f,g) treated with Ad-mTff2 showed lower numbers of tumours compared with control mice after AOM/DSS treatment, four experiments
with n¼4–5 mice in each group, **Po0.01, unpaired t-test, two-tailed or Holms-Sidak’s multiple comparison test after analysis of variance test.
(h) Signiﬁcant reduction in the dysplasia area in wild-type mice, n¼ 3–6 mice in each group, *Po0.05, unpaired t-test, two-tailed. (i) Hematoxylin and
eosin staining of colon from wild-type mice with Ad-Fc and Ad-Tff2 injections.
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protocols were in accordance to guidelines by the National Institutes of Health and
approved by the Institutional Animal Care and Use Committee at Columbia
University. The TFF2–BAC–EGFP–Cre transgenic mice were generated by BAC
recombineering (clone RP23-332C16 purchased from Children’s Hospital Oakland
Research Institute), as previously described41. Recombineering primers ampliﬁed
the EGFP–Cre–pA–fNf cassette with 60 bp homology arms upstream and
downstream of the TFF2 translational stop codon in exon 4. We generated three
founder lines, all of which displayed a similar pattern of expression throughout
various organs (stomach, pancreas and spleen). As a result, all lines were
backcrossed six generations to C57BL/6 J and Line 3a used for all experiments
performed here according to the guidelines of the Institute of Comparative
Medicine at Columbia University.
Induction of colitis. In the experiments involving DSS-induced colitis, 8 to 12
weeks old sex-matched Tff2-null, CD2–Tff2 and wild-type mice were used unless
speciﬁed otherwise. For induction of chronic colitis, Tff2-null, CD2–Tff2 and wild-
type mice were given 2.5% DSS (molecular weigh 36,000–50,000; MP Biomedicals,
Solon, OH, USA) dissolved in drinking water provided ad libitum for 5 days,
followed by plain water for next 14 days. Mice were analysed at day 19.
Tumour model. Mice (age 6–8 weeks) were injected intraperitoneally (i.p.) with
AOM (10mg kg 1 body weight) and after 1 week 2.5% DSS water was given for 7
days. Mice were killed 5 months later. For experiments with adenovirus system,
mice were injected with AOM/DSS as above, and then they were treated with one
dose of Ad-mTff2 (5 108 p.f.u. per mouse) every 2 weeks via tail injection and
analysed 3 months later. Macroscopically visible tumours were counted and their
sizes were measured. Colon sections were analysed for histopathology scoring.
Vagus nerve stimulation. Mice were anaesthetised with ketamine (100mg kg 1)
and xylazine (10mg kg 1) i.p. A midline abdominal incision was made and the left
subdiaphragmatic vagus nerve trunk was isolated. Two bipolar platinum electrodes
were applied to the nerve (Plastics One). Electrical stimulation was delivered at 1 V,
2ms, 5Hz for 240min by a stimulation module (STM100A) controlled by the
AcqKnowledge software (Biopac Systems). The abdomen is closed in two layers. In
Sham-operated animals only an abdominal incision was made and the left sub-
diaphragmatic vagus nerve trunk isolated. Depth of anaesthesia was monitored by
the hind paw reﬂex and adapted by titrating ketamine and xylazine when mice
regained the reﬂex. Four hours after vagus nerve stimulation yohimbine
(2mg kg 1) was administered. Mice were euthanized 180min later and spleen was
harvested.
Bilateral subdiaphragmatic truncal vagotomy and pyloroplasty. Mice were
anaesthetised with ketamine (100mg kg 1) and xylazine (10mg kg 1) i.p. A
midline abdominal incision was made and the vagotomy was performed by
dividing and cutting both vagal trunks immediately below the diaphragm. To
prevent food retention and fatal gastric dilatation a pyloroplasty was performed by
cutting the pylorus lengthwise and closing it in a perpendicular fashion using two
single 8–0 non-absorbable sutures. The abdominal cavity was closed in a two layer
fashion. In control animals (Sham operation), the subdiaphragmatic vagal nerves
were isolated but not cut and a pyloroplasty was performed.
Splenic denervation. Three-week-old C57BL/6 mice were injected with AOM
(azoxymethan) 10mg kg 1 and 3 weeks later SpDnx was performed as follows.
Mice were anaesthetised using isoﬂurane. A midline laparotomy allowed
exteriorization of the pancreatic tail after mobilizing the spleen. After dissecting the
pancreas until the level of the portal vein, the coeliac artery and the branching of
the splenic artery were identiﬁed. The nerve bundles were subtly removed using
micro-surgical instruments under an operating microscope (magniﬁcation  25).
After careful irrigation of the entire abdominal cavity with 0.9% sterile and pre-
warmed saline, the sutures was checked for cessation of bleeding and the procedure
was ended by closing the abdominal muscles using 5–0 vicryl sutures (Ethicon),
and the skin was stapled using 9.0-mm staples (Reﬂex Skin Closure Systems). A
total of 0.1mg kg 1 buprenorphine–HCl in normal saline was injected sub-
cutaneously for analgesia. Mice were given 2 weeks to recover after surgery and
AOM was injected twice (5mg kg 1) with interval 1 week between injections.
Then mice were given three cycles of 1.5% DSS for 7 days with tap water between
DSS. Mice were sacriﬁced after 4.5–5 months.
Permeability measurement. Mice were given 2.5% DSS water during 5 days, and
then FITC-dextran 4000 was injected as follows. After anaesthesia, a midline
laparotomy incision was made. A 2-cm long segment of the colon inside was
created with two vascular hemoclips without disrupting the mesenteric vascular
arcades. The length of the intestine between two clips was injected with 50 ml of
100mgml 1 FITC-dextran 4000 (Sigma-Aldrich) solution per mouse. Mice
were sacriﬁced after 1 h and ﬂuorescence was measured in the plasma with a
ﬂuorimeter. Dilutions of FITC-dextran in normal mouse serum were used as a
standard curve, and absorption of 100 ml of serum or standard was measured in a
ﬂuorometer at 488 nm.
Cell sorting. Splenic CD11bþGr-1þ cells were labelled with PerCP
5.5-conjugated Gr-1 and APC-conjugated CD11b antibodies and sorted using
sorter FASCAria.
Depletion of CD8 cells in vivo. Four weeks after AOM/DSS treatment mice were
injected i.p. with anti-mouse CD8a antibody (clone 53.6.72, BioXcell) or corre-
sponding isotypic control (clone 2A3, BioXcell) at 12mg kg 1 in sterile DPBS
twice weekly for 12 weeks.
MDSC adoptive transfer. For experiments of MDSC adoptive transfer, CD2–Tff2
mice were injected with AOM (10mg kg 1), and a week later were treated twice
with 2.5% DSS during 7 days with weekly interval between two treatments. Two
weeks later CD11bþGr-1þ from spleens of Tff2-null tumour-bearing mice were
labelled with antibody CD11b–APC and Gr-1–PerCP5.5 and sorted by using
FASC Aria (BD Bioscience), and then sorted cells were intravenously injected into
CD2–Tff2 (2–3 106 per mouse) once a week during 6 weeks. Mice were analysed
5 months after treatment with AOM.
Adoptive transfer of IMC from Tff2-null mice and from CD2–Tff2 mice.
Wild-type mice (CD45.1) were treated AOM/DSS and after 13 weeks injected with
CD11bþGr-1þ cells (3 106 per mouse) sorted from spleens of naive Tff2-null
and CD2–Tff2 mice. Mice were analysed 5 weeks later.
Bone marrow transplantation. Mice were lethally irradiated with single dose 9Gy
and 6 h later were reconstituted with bone marrow cells (3.5–5 106 per mouse) by
tail vein injection. Transplanted mice were allowed to rest 4 weeks before
administration of DSS (2.5%) or AOM/DSS protocols. In tumour studies mice were
injected AOM and then were treated with three cycles of 2% DSS water.
Histopathology. Formalin-preserved colons were processed and embedded in
parafﬁn according to standard procedures. Colon and tumour sections (5 mm) were
stained with hematoxylin and eosin and examined by a pathologist blinded to the
experimental groups.
NO and ROS analysis. For NO analysis 100 ml of culture supernatant were mixed
with equal volume of Griess agent and nitrite concentrations were measured
by comparing the absorbance values of the test sample with standard curve.
Absorbance was measured at 550 nm after 15min incubation at room temperature.
The production of ROS in MDSCs was determined with the dye 29,79-
dichloroﬂuorescein diacetate (Sigma-Aldrich). Cells from mice treated with
AOM/DSS were incubated at 37 C in RPMI 1640 in the presence of 2.0mM
29,79-dichloroﬂuorescein diacetate for 30min, then labelled with antibody
CD45–PE–Cy7, CD11b–APC, Gr-1–PerCP5.5 for 20min. Analysis was then
performed by ﬂow cytometry.
Immunohistochemistry. For granulocyte and Ki67 staining, formalin-ﬁxed
parafﬁn-embedded spleens were stained with anti-Gr-1 (Ly-6G/Ly-6C, clone
RB6-8C5) antibody labelled with biotin (dilution 1:200, BioLegend), anti-mouse
Ki67 antibody (dilution 1:200) and secondary antibodies (dilution 1:200, Dako).
For CD44 and TFF2 immunostaining 250 mg blefeldin A was injected
intravenously into wild- type mice 6 h before sacriﬁced42. Splenic cryosections were
incubated with goat anti-mouse CD44 (1:1,000, BD) and rabbit afﬁnity-puriﬁed
antibody against C-terminal part of molecule (0.01 mgml 1) for 2 h. After washing
with PBS-Tween 20, the sections were when incubated with Alexa Fluor 594-
conjugated anti-rabbit IgG and Alexa Fluor 488-conjugated anti-goat IgG (BD) for
1 h. Subsequently, splenic cryosections were stained with 4,6-diamidino-2-
phenylindole (BD) at 0.1mgml 1 and observed by ﬂuorescence microscopy with
420 and 590 nm ﬁlters.
FACS analysis. Cells were labelled with appropriate antibodies and sorted using
sorter FASCAria (Becton Dickinson). Phycoerythrin (PE)-conjugated anti-mouse-
CD11c (clone N418), -CD86 (clone GL1), -CD80 (clone 16-10A1), -CD31
(clone 390), -CD40 (clone 1c10), -major histocompatibility complexII (clone I-A),
-CD115 (clone AFS98), -F4/80 (clone BM8) (from eBioscience). Anti-mouse
PE–Cy7–CD8a (clone 53-6.7), Alexa Flour 700-CD4 (clone GK1.5), APC–Cy7–
CD3e (clone 145-2C11), PerCP–Cy 5.5–Gr-1 (Ly-6G/Ly-6C, clone RB6-8C5),
APC–CD11b (clone M1/70), PE/Cy7–CD45 (clone 30-F11), FITC–Ly-6G (clone
RB6-8C5) were purchased from PharMingen or Biolegend, PerCP/Cy5.5–CD16/32
(clone 93), Paciﬁc Blue Ms CD3/Ly-6G(Ly-6C)/CD11b/CD45R(B220)/Ter-119,
PE/Cy7–CD117 (clone 2B8), APC–CD115 (clone AfS98), PE–CD127 (clone
A7R34), APC–Cy7–Ly6A/E (clone D7), FITC–CD34 (clone RAM34), APC–CD4
(clone RM4-5), FITC–CD44 (IM7), PerCP/Cy5.5–CD62L (MEL-14) were
purchased from PharMingen, eBiocsience or Biolegend. Dead cells were
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discriminated using 4,6-diamidino-2-phenylindole. Samples were analysed on
LSRII ﬂow cytometer and the data ﬁles were analysed using FlowJo 5.5.5 software.
ELISPOT assay. Sorted spleen CD8þ T cells from either Tff2-null or CD2–Tff2
AOM/DSS-treated tumour-bearing mice were mixed with irradiated naive
splenocytes at 1:1 ratio. Cells were then stimulated with 1 mgml 1 each anti-CD3/
CD28 antibodies (Biolegend) for 48 h. ELISPOT assay was performed by using
Mouse IFN-g/Granzyme B dual-color Elispot kit (R&D Systems) according to
manufacturer’s instructions. Plates were scanned and counted for INF-g or
Granzyme B stained dots.
Semi-quantitative and qRT–PCR. Splenic T and B cells were isolated from wild-
type mice by negative selection using immunomagnetic separation kit (Myltenyi
Biotech, Inc.). To conﬁrm the validity of separation procedure total mRNA was
extracted from T- and B-cell population and subjected to semi-quantitative PCR
analysis for T and B cell-speciﬁc marker Thy 1.2 and CD19, respectively. Total RNA
was isolated and reverse transcribed to cDNA with Superscript III (Invitrogen,
Carlsbad, USA). Selected ApoE and three cell cycle related genes (cyclin D1, cyclin
E1, Nupr 1), which differential expression in TFF2 treated cells was identiﬁed by
microarray hybridization analysis, were tested by the real-time qRT–PCR assay.
Mouse TFF2 primers (50-GTCAGCTCGCAAGAATTGTG-30 , (exon 3–4)
50-GGCAGTAGCAACTCTCAGTA-30 , probe: 50-/56-FAM/CAGGGCACT/ZEN/
TCAAAGATCAGGTTGGA/3IABkFQ/-30) mouse CD8b1 primers: (50-TGGCCG
TCTACTTTTACTGTG-30 , (exon 5–6) 50-GGCGCTGATCATTTGTGAAAC-30 ,
probe: 50-/56-FAM/TGAAGTGAA/ZEN/TTCGGGCTCTCCTCC/3IABkFQ/-30);
mGAPDH primers: IDT Mm.PT.39a.1 (exon 2–3), TaqMan Universal PCR
Master mix.
Mouse ApoE / primers (50-GATCCGATCCCCTGCTCAGA-30 ; 50-TCT
GTCACCTCCGGCTCTCC-30), cyclin E1 (50-TTCAGCCTCG GAAAATCA
GACC-30 ; 50-GCACACCTCCATTAGCCAATCC-30), Nupr1 (50-GGTCGGACC
AAGAGAGAAGCTG-30 ; 50-TGGTGTCTGTG GTCTGGCCTTA-30), IL-1b (50-C
AACCAACAAGTGATATTCTCCATG-30 ; 50-GATCCACACTCTCCAGCTGCA-
30), IL-17A (50-TCCAGAATGTGAAGGTCAACC-30 ; 50-TATCAGGGTCTTCAT
TGCGG-30), and reference gene GAPDH (50-ACGGACCCCAAAAGATGAAG-30 ;
50-TTCTCCACAGCCACAATGAG-30), Mastermix (Qiagen) with SYBR Green.
For calculation of fold augmentation RNA amounts were normalized to
GAPDH mRNA. Assays were performed on ABI 7500 thermal cycler (Applied
Biosystem). Results were calculated using 2 ddCt formula. Statistical signiﬁcance of
different gene expression (dCt) was evaluated using Student’s t-test for paired
samples.
When sorted CD11bþGr-1þ cells were used total mRNA was isolated by using
RNAqueus-micro Kit (Ambion, Grand Island, NY).
CD11bþ Gr-1þ cells proliferation assay. CD11bþ Gr-1þ cell proliferation was
determined using BrdU Cell Proliferation Assay Kit (Calbiochem, Germany) or
mRNA cyclin D1 was quantiﬁed by qRT–PCR. Live CD11bþGr-1þ cells from
DSS-induced (day 19) or tumour-bearing mice were sorted from spleen and
cultured 7 days in complete RPMI 1640 medium (Invitrogen) supplemented with
10% FCS (HyClone), 50 mM b-mercaptoethanol, 1mM penicillin-streptomicin,
GM-CSF in concentrations 2.5 ngml 1. Recombinant mouse TFF2 was added in
concentration as indicated. Every 48 h half of medium was replaced with fresh
culture medium. Cell proliferation was determined by addition of BrdU during the
ﬁnal 18 h of culture accordingly protocol of manufacture. When speciﬁed,
CD11bþ Gr-1þ cells were preincubated for 30min with AMD3100 (0.6 mM ﬁnal
concentration) or antibody CD80 (10 mgml 1) on ice, then cells were cultured as
above.
T cell proliferation assay. CD4þ T cells were sorted from untreated Tff2-null-
mice and stimulated with 2.5 mgml 1 plate-bound anti-CD3 and 2.5 mgml 1
CD28 antibodies (BD Pharmigen) for 24 h. Live CD11bþGr-1þ cells were sorted
from spleen of Tff2-null AOM/DSS-treated mice (5–6 months after treatment) and
cultured at indicated ratios with activated T cells in 96-well ﬂat bottom plates in
complete RPMI 1640 medium (Invitrogen) supplemented with 10% FBS, 10mM
HEPES, 1mM penicillin-streptomycin and 50 mM b-mercaptoethanol. T cells
proliferation was assessed after 72 h culture by pulsing with BrdU during the ﬁnal
18 h of culture accordingly protocol of manufacture (Calbiochem, Germany).
Supernatant was used for IFN-g measurement by using commercial BD OptEIA
Set kits (BD Biosciences, Sydney, Australia).
Generation of adenovirus expressing mTff2. Adenoviral vector (pAdlox),
recombinant Ad-GFP and Ad-Fc (human Fc fragment of IgG1) were kindly
provided by Dr Jan Kitajewski (Columbia University, NYC). The full-length mTff2
cDNA fragment was generated by PCR ampliﬁcation using phCMV3-mTff2
construct and subcloned into pAdlox vector by In-fusion HD Cloning Kit
(Clontech Co.). The construct of pAdlox-mTff2 was conﬁrmed by DNA
sequencing, then, linearized by SﬁI and packaged in HEK293 cells. The expression
of recombinant mTff2 in 293 cells was veriﬁed by western blot. All of the viral
particles were puriﬁed by caesium chloride density gradient centrifugation and
titrated by TCID50 method.
Microarray analysis. Splenic CD11bþGr-1þ cell were sorted by ﬂow cytometry
from spleens of Tff2-null mice (n¼ 4) taken on day 19 after single cycle with 3%
DSS and split into two halves. One half was cultured for 7 days at density 1 106
cells per ml in 3ml complete RPMI 1640 medium (10% FCS, ES grade, Invitrogen)
supplemented with GM-CSF (2.5 ng ml 1) alone while another half with an
addition of 3 mM of mouse rTFF2. mRNA from eight samples was puriﬁed by using
Trizol reagent (Invitrogen). Total RNA was reverse transcribed, ampliﬁed, labelled
and hybridized to Mouse Genome 430A 2.0 arrays (Affymetrix) at The Core
Facility of Columbia University. Data from the hybridized chips were scanned and
analysed using Bioconductor and R software43,44. All eight chips passed
recommended QC tests45. Normalization was performed using GCRMA46,47and
statistical analysis was performed using Limma43. 5,810 transcripts which were
differentially expressed with a Benjamini-Hochberg False Discovery Rate48,
fdro0.05 were found. The array data was deposited in the Gene Expression
Omnibus, accession number GSE47596.
Western blotting. Tissues (spleen, stomach mucosa, thymus, colon) were
collected in RIPA lysis buffer supplemented with complete protease inhibitor
cocktail (Roche) and homogenized. CD4þ T cells were isolated from spleen of
wild-type mice on day 3 after treatment with 3% DSS and stimulated with cell
activation cocktail (with brefeldin A) for 16 h. Samples were resolved by 18%
SDS–PAGE and transferred to 0.2-mm pore-size PVDF membrane (Immobilon-
Psq, Millipore). Membranes were blocked in 5% non-fat milk, incubated overnight
at 4 C with rabbit antibodies raised against C-end of mouse TFF2 molecule
(1 mgml 1) and probed with horseradish peroxidase-tagged secondary antibodies.
Blots were developed with SuperSignal West Femto Maximum Sensitivity Substrate
Kit (Pierce ECL). (Supplementary Figures 11).
Cytokine ELISA. Elisa assay was performed with commercial BD OptEIA Set kits
(BD Biosciences, Sydney, Australia).
In vivo bromodeoxyuridine labelling. Mice were subjected to DSS protocol to
induce colitis, and then injected with BrdU i.p. (1mg per 20 g body weight) 3 h
before killing them. Splenic cells were stained for CD11bþ , Gr-1þ and
intracellular BrdU staining was performed by using FITC BrdU ﬂow kit
(BD Pharmigen, San Diego) according to manufacturer’s instructions.
Statistical analysis. Graphs and analyses were calculated using GrapPadPrism.
P values were determined by using two-tailed unpaired Student’s t-test. For three or
more groups an analysis of variance followed by Sidak’s or Holm–Sidak’s multiple
comparison test or Kruskal–Wallis test was performed. The following designations
apply to all ﬁgures: NS, non-signiﬁcant, *Po0.05, **Po0.01, ***Po0.001,
****Po0.0001. P valueso0.05 were considered signiﬁcant. Statistical analysis of
survival curves was performed using log-rank test.
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